Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 21 articles: HTML format

Single Articles

August 2025
1. BANCROFT EK, McHugh JK, Eeles RA
   Screening for Prostate Cancer with a Polygenic Risk Score. Reply.
   N Engl J Med. 2025;393:832.
   PubMed    
   
   
   
2. GREEN HD, Jackson L, Bailey SER
   Screening for Prostate Cancer with a Polygenic Risk Score.
   N Engl J Med. 2025;393:831-832.
   PubMed    
   
   
   
3. SU CY, Hasebe M
   Screening for Prostate Cancer with a Polygenic Risk Score.
   N Engl J Med. 2025;393:831.
   PubMed    
   
   
   
4. EKLUND M, Thompson IM Jr, Cooperberg MR
   Screening for Prostate Cancer with a Polygenic Risk Score.
   N Engl J Med. 2025;393:831.
   PubMed    
   
   
   
5. 
   Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
   N Engl J Med. 2025 Aug 1. doi: 10.1056/NEJMx250003.
   PubMed    
   
   
   April 2025
6. MCHUGH JK, Bancroft EK, Saunders E, Brook MN, et al
   Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
   N Engl J Med. 2025;392:1406-1417.
   PubMed     Abstract available
   
   
   January 2025
7. VAN AS N, Patel J, Hall E
   Stereotactic Body Radiotherapy in Localized Prostate Cancer. Reply.
   N Engl J Med. 2025;392:206-207.
   PubMed    
   
   
   
8. KASHIHARA T
   Stereotactic Body Radiotherapy in Localized Prostate Cancer.
   N Engl J Med. 2025;392:206.
   PubMed    
   
   
   December 2024
9. HUGOSSON J, Godtman RA, Stranne J
   Four Years of Screening for Prostate Cancer with PSA and MRI. Reply.
   N Engl J Med. 2024;391:2274.
   PubMed    
   
   
   
10. TILKI D, Chen MH, D'Amico AV
    Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:2273-2274.
    PubMed    
    
    
    October 2024
11. VAN AS N, Griffin C, Tree A, Patel J, et al
    Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2024;391:1413-1425.
    PubMed     Abstract available
    
    
    
12. HOLMBERG L, Garmo H, Andersson SO, Andren O, et al
    Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    N Engl J Med. 2024;391:1362-1364.
    PubMed    
    
    
    September 2024
13. PINSKY PF
    Prostate Biopsy in Men with an Elevated PSA Level - Reducing Overdiagnosis.
    N Engl J Med. 2024;391:1153-1154.
    PubMed    
    
    
    
14. HUGOSSON J, Godtman RA, Wallstrom J, Axcrona U, et al
    Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:1083-1095.
    PubMed     Abstract available
    
    
    
15. GANGULI I
    How Does Health Care Burden Patients? Let Me Count the Days.
    N Engl J Med. 2024;391:880-883.
    PubMed    
    
    
    August 2024
16. ARENAS-GALLO C, Michie M, Jones N, Pronovost PJ, et al
    Race-Based Screening under the Public Health Ethics Microscope - The Case of Prostate Cancer.
    N Engl J Med. 2024;391:468-474.
    PubMed    
    
    
    January 2024
17. SHORE ND, Tarazi J, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2024;390:90-91.
    PubMed    
    
    
    
18. POLLAK M
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2024;390:90.
    PubMed    
    
    
    October 2023
19. APARICIO A
    Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
    N Engl J Med. 2023;389:1522-1523.
    PubMed    
    
    
    
20. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2023;389:1453-1465.
    PubMed     Abstract available
    
    
    
21. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
    Decision Making in Prostate Cancer.
    N Engl J Med. 2023;389:1335-1338.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.